Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,615,494 papers from all fields of science
Search
Sign In
Create Free Account
LY 355703
Known as:
LY-355703
, LY355703
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
cryptophycin 52
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum‐resistant ovarian cancer
G. D'agostino
,
J. D. Del Campo
,
+5 authors
G. Scambia
International journal of gynecological cancer…
2006
Corpus ID: 20335729
LY355703 is a synthetic product structurally related to the cryptophycin family isolated from the blue-green algae, which exerts…
Expand
2004
2004
Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity.
R. Al-awar
,
T. Corbett
,
+4 authors
Daniel C Williams
Molecular cancer therapeutics
2004
Corpus ID: 23858133
Cryptophycin 52 (LY355703) is a potent antiproliferative analogue of the marine natural product cryptophycin 1. It has been shown…
Expand
Highly Cited
2003
Highly Cited
2003
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
M. Edelman
,
D. Gandara
,
+4 authors
L. Doyle
Lung cancer
2003
Corpus ID: 1239671
2003
2003
Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent.
Arun K. Ghosh
,
L. Swanson
The Journal of organic chemistry
2003
Corpus ID: 1706483
A highly enantioselective and convergent synthesis of cryptophycin 52 (2), an exceedingly potent cytotoxic agent, is described…
Expand
Highly Cited
2002
Highly Cited
2002
Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
C. Sessa
,
K. Weigang-Köhler
,
+6 authors
R. Johnson
European journal of cancer
2002
Corpus ID: 20510563
2002
2002
The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
L. Drew
,
R. Fine
,
Tamara N Do
,
Geoffrey P Douglas
,
D. Petrylak
Clinical cancer research : an official journal of…
2002
Corpus ID: 17270604
We assessed the ability of cryptophycin 52 (LY355703), a novel antimicrotubule, to induce growth arrest and apoptosis in prostate…
Expand
2002
2002
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
J. Stevenson
,
Weijing Sun
,
+9 authors
P. O'dwyer
Clinical cancer research : an official journal of…
2002
Corpus ID: 14377874
The cryptophycin analogue LY355703 is a potent inhibitor of microtubule polymerization that displays in vitro and in vivo…
Expand
2000
2000
Interaction of the antitumor compound cryptophycin-52 with tubulin.
D. Panda
,
V. Ananthnarayan
,
G. Larson
,
C. Shih
,
M. Jordan
,
L. Wilson
Biochemistry
2000
Corpus ID: 24142110
Cryptophycin-52 (LY355703) is currently undergoing clinical evaluation for cancer chemotherapy. It is a potent suppressor of…
Expand
Highly Cited
1999
Highly Cited
1999
In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines
M. M. Wagner
,
D. Paul
,
C. Shih
,
M. Jordan
,
L. Wilson
,
D. Williams
Cancer Chemotherapy and Pharmacology
1999
Corpus ID: 30945183
Purpose: Cryptophycin 52 (LY355703) is a new member of the cryptophycin family of antitumor agents that is currently undergoing…
Expand
Highly Cited
1998
Highly Cited
1998
Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
D. Panda
,
K. Deluca
,
D. Williams
,
M. Jordan
,
L. Wilson
Proceedings of the National Academy of Sciences…
1998
Corpus ID: 9334450
Cryptophycin-52 (LY355703) is a new synthetic member of the cryptophycin family of antimitotic antitumor agents that is currently…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE